You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors
  1. Georges Al-Helou,
  2. Nardos Temesgen,
  3. Jonathan Gwizdala,
  4. Jalil Ahari
  1. Pulmonary and Critical Care, George Washington University, Columbia, Washington, DC, USA
  1. Correspondence to Dr Georges Al-Helou, gre05{at}gwu.edu

Summary

Our patient is a 69-year-old man who presented to the emergency department with left-sided hemiparesis that started 4 hours prior to presentation. Brain CT showed right basal ganglia and internal capsule haemorrhagic strokes. MRI revealed multiple brain lesions suspicious for metastases. Further workup revealed a 5 cm lung mass and a 1 cm pancreatic nodule. Biopsy of both pulmonary and pancreatic lesions was consistent with melanoma and was similar histologically. The patient underwent cyberknife stereotactic radiosurgery to the brain metastases followed by immunotherapy with pembrolizumab, and then by nivolumab and ipilimumab. The patient remains free of disease progression 2 years after treatment.

  • respiratory medicine
  • cancer intervention
  • lung cancer (oncology)

https://doi.org/10.1136/bcr-2017-223025

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JA was involved in the manuscript planning, literature review, drafting of manuscript and case review. NT was involved in case review, data collection and manuscript drafting. JG was involved in literature review and drafting of manuscript. GAH is the corresponding author and was involved in literature review, and drafting and editing the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.